Congress Demands Answers on Data Privacy Ahead of 23andMe Sale

In the wake of the news that genetic testing company 23andMe is being acquired by a pharmaceutical company, Congress is demanding answers on data privacy concerns.

The sale has raised concerns about the privacy of the vast amount of genetic data held by 23andMe and how it will be used by the pharmaceutical company.

Congress is calling for transparency and assurance that individuals’ genetic information will be protected and not used for profit without their consent.

Lawmakers are also seeking information on how 23andMe plans to secure sensitive genetic data and prevent it from being exploited by third parties.

There are fears that the sale of 23andMe could set a dangerous precedent for the handling of personal genetic information and erode trust in the privacy of such data.

Congress is expected to hold hearings to address these concerns and ensure that appropriate safeguards are in place to protect the privacy of individuals’ genetic data.

The outcome of these hearings could have far-reaching implications for the regulation of genetic testing companies and the protection of individuals’ data in the future.

It is crucial that lawmakers take action to address these concerns and hold companies accountable for protecting the privacy of individuals’ genetic information.

Only through robust regulation and oversight can we ensure that genetic data is used responsibly and ethically for the benefit of all.

As the sale of 23andMe moves forward, it is essential that Congress acts swiftly to address these data privacy concerns and uphold the rights of individuals to control their own genetic information.